این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Physiology and Pharmacology، جلد ۲۹، شماره ۲، صفحات ۱۱۱-۱۲۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Enhancing Clinical Outcomes and Survival in Hospitalized Multiple Sclerosis Patients with COVID-19: Challenges of Antiviral Therapy
چکیده انگلیسی مقاله Introduction: This study aimed to evaluate the efficacy and safety concerns of remdesivir and type 1 interferons on the clinical outcomes of hospitalized multiple sclerosis patients with COVID-19.
Methods: Using electronic health records systems; this is a cross-sectional study of two years of hospital admissions in terms of COVID-19 in Iran from March 2019 to August 2021. The severities of COVID-19 outcomes were ICU admission, hospitalization days, and 30-day survival rates.
Results: A total of 993 hospitalized multiple sclerosis patients with a confirmed diagnosis of COVID-19 based on PCR testing were recorded in the electronic health systems. Nearly half of these patients (50.3%) had received treatment with an anti-CD20 agent (rituximab or ocrelizumab) at the hospital admission. This group exhibited higher mortality rates, increased need for ICU admission, and longer hospitalization (p<0.05).
There was a significant association between taking interferon-β1 alone (adjusted IRR=1.21, 95% CI 1.32 to 1.42) or in combination with remdesivir (adjusted IRR=1.30, 95% CI 1.18 to 1.5042) and longer hospitalization.
There were no significant associations between antiviral treatment (remdesivir alone, interferon-β1- β1 alone, and interferon-β1plus remdesivir) and ICU admission (p>0.2), the in-hospital mortality rate (p>0.2), or 30-day survival rate (p>0.2). The results were similar in patients who did or did not receive anti-CD20 agents. These results were consistent among patients regardless of whether they received anti-CD20 agents.
Conclusion: Our data suggest that remdesivir, interferon-β1, or a combination of both does not benefit hospitalized MS patients with COVID-19.
کلیدواژه‌های انگلیسی مقاله Multiple sclerosis ,COVID-19 ,Remdesivir ,Interferon ,Anti-CD20 agents
نویسندگان مقاله | Zhila Maghbooli
Neuroscience Institute, Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran


| Amir Kasaeian
Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran


| Mohammad Reza Fattahi
Neuroscience Institute, Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran


| Tarlan Varzandi
Neuroscience Institute, Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, IRAN


| Sara Hamtaeigashi
Neuroscience Institute, Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, IRAN


| Sara Mohammadnabi
Neuroscience Institute, Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, IRAN


| Mohammad Ali Sahraian
Neuroscience Institute, Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, IRAN
نشانی اینترنتی http://ppj.phypha.ir/browse.php?a_code=A-10-2472-1&slc_lang=en&sid=1
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده Neurophysiology/Pharmacology
نوع مقاله منتشر شده Clinical research article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات